Voro Therapeutics is a privately held biotechnology company based in San Diego and Boston, spun out of Alloy Therapeutics’ 82VS Venture Studio. PrimeBody™ is a next-generation tumor-activated biologics platform that enables systemic delivery with activation restricted to the tumor microenvironment, driving safer and more durable anti-tumor responses. Voro’s lead asset, the first Fc-enhanced, high-affinity CD47 blocker, shows curative activity without the historical safety or exposure limitations of this target and is advancing through IND-enabling studies with a defined clinical strategy. Applicable to cytokines, TCEs, and ADCs, PrimeBody™ supports a diversified pipeline.

Voro Therapeutics

Org chart

Teams

Offices